Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition.

Rahman MA, Kuse N, Murakoshi H, Chikata T, Gatanaga H, Oka S, Takiguchi M.

Microbes Infect. 2014 May;16(5):434-8. doi: 10.1016/j.micinf.2014.03.003. Epub 2014 Mar 20.

PMID:
24657622
[PubMed - in process]
2.

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I, de Mendoza C.

Antiviral Res. 2011 Jun;90(3):164-7. doi: 10.1016/j.antiviral.2011.03.178. Epub 2011 Mar 23.

PMID:
21439330
[PubMed - indexed for MEDLINE]
3.

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, Parker K, Mullins JI, Sow PS, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group.

PLoS One. 2012;7(9):e45372. doi: 10.1371/journal.pone.0045372. Epub 2012 Sep 18.

PMID:
23028968
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals.

Hashimoto M, Kitano M, Honda K, Koizumi H, Dohki S, Oka S, Takiguchi M.

Hum Immunol. 2010 Feb;71(2):123-7. doi: 10.1016/j.humimm.2009.10.015. Epub 2009 Nov 3.

PMID:
19891998
[PubMed - indexed for MEDLINE]
5.

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.

PMID:
18227187
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Characterization and structural analysis of HIV-1 integrase conservation.

Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.

AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.

PMID:
19290031
[PubMed - indexed for MEDLINE]
7.

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y.

Biochemistry. 2008 Sep 9;47(36):9345-54. doi: 10.1021/bi800791q. Epub 2008 Aug 15.

PMID:
18702518
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Selection of escape mutant by HLA-C-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication.

Honda K, Zheng N, Murakoshi H, Hashimoto M, Sakai K, Borghan MA, Chikata T, Koyanagi M, Tamura Y, Gatanaga H, Oka S, Takiguchi M.

Eur J Immunol. 2011 Jan;41(1):97-106. doi: 10.1002/eji.201040841. Epub 2010 Dec 3.

PMID:
21182081
[PubMed - indexed for MEDLINE]
9.

Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS.

Tomiyama H, Miwa K, Shiga H, Moore YI, Oka S, Iwamoto A, Kaneko Y, Takiguchi M.

J Immunol. 1997 May 15;158(10):5026-34.

PMID:
9144523
[PubMed - indexed for MEDLINE]
10.

Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition.

Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, Walter H, Schmidt B, Arnold ML, Harrer EG, Kaiser R, Schweitzer F, Braun P, Reuter S, Jaeger H, Wolf E, Brockmeyer NH, Jansen K, Michalik C, Harrer T; German Competence Network for HIV/AIDS.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):109-17. doi: 10.1097/QAI.0b013e3181fe946e.

PMID:
21107269
[PubMed - indexed for MEDLINE]
11.

Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1.

Ikeda-Moore Y, Tomiyama H, Miwa K, Oka S, Iwamoto A, Kaneko Y, Takiguchi M.

J Immunol. 1997 Dec 15;159(12):6242-52.

PMID:
9550428
[PubMed - indexed for MEDLINE]
12.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF.

Retrovirology. 2011 Aug 19;8:68. doi: 10.1186/1742-4690-8-68.

PMID:
21854605
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients.

Fukada K, Tomiyama H, Wasi C, Matsuda T, Kusagawa S, Sato H, Oka S, Takebe Y, Takiguchi M.

AIDS. 2002 Mar 29;16(5):701-11.

PMID:
11964526
[PubMed - indexed for MEDLINE]
14.

Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B∗4002-restricted T cells.

Watanabe T, Murakoshi H, Gatanaga H, Koyanagi M, Oka S, Takiguchi M.

Microbes Infect. 2011 Feb;13(2):160-6. doi: 10.1016/j.micinf.2010.10.006. Epub 2010 Nov 4.

PMID:
20971209
[PubMed - indexed for MEDLINE]
15.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

PMID:
23529738
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

Cardinaud S, Consiglieri G, Bouziat R, Urrutia A, Graff-Dubois S, Fourati S, Malet I, Guergnon J, Guihot A, Katlama C, Autran B, van Endert P, Lemonnier FA, Appay V, Schwartz O, Kloetzel PM, Moris A.

PLoS Pathog. 2011 May;7(5):e1002049. doi: 10.1371/journal.ppat.1002049. Epub 2011 May 12.

PMID:
21589903
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.

Abdel-Motal UM, Friedline R, Poligone B, Pogue-Caley RR, Frelinger JA, Tisch R.

Clin Immunol. 2001 Oct;101(1):51-8.

PMID:
11580226
[PubMed - indexed for MEDLINE]
18.

Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes.

Mason RD, Bowmer MI, Howley CM, Gallant M, Myers JC, Grant MD.

J Immunol. 2004 Jun 1;172(11):7212-9.

PMID:
15153547
[PubMed - indexed for MEDLINE]
Free Article
19.

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.

Gatanaga H, Murakoshi H, Hachiya A, Hayashida T, Chikata T, Ode H, Tsuchiya K, Sugiura W, Takiguchi M, Oka S.

Clin Infect Dis. 2013 Oct;57(7):1051-5. doi: 10.1093/cid/cit430. Epub 2013 Jun 23.

PMID:
23797286
[PubMed - indexed for MEDLINE]
20.

Interdisciplinary analysis of HIV-specific CD8+ T cell responses against variant epitopes reveals restricted TCR promiscuity.

Hoof I, Pérez CL, Buggert M, Gustafsson RK, Nielsen M, Lund O, Karlsson AC.

J Immunol. 2010 May 1;184(9):5383-91. doi: 10.4049/jimmunol.0903516. Epub 2010 Apr 2.

PMID:
20363973
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk